The overwhelming improvement in the prognosis of advanced Hodgkin's disease (HD) brought about by the introduction of 'MOPP'-like cyclical combination chemotherapy appropriately led to this becoming established as the chemotherapy of choice for the ensuing two decades (DeVita et al.. 1970 : Nicholson et al.. 1970 : Sutcliffe et al.. 1978 : Longo et al.. 1986 Hancock. 1986; McKendrick et al.. 1989 : Selby et al.. 1990 Ranson et al.. 1991) . In the meantime. the drawbacks of the treatment have become gradually apparent. It fails. to some extent. for at least one-third of the patients. either because remission. the major prerequisite for improving on the natural history is not achieved, or because recurrence occurs. It is unpleasant to receive and there are long-term complications of infertility (Chapman et al.. 1979 : Horning et al.. 1981 ) and development of second malignancy (Coleman. 1986; Dorreen et al.. 1986; Tucker et al.. 1988 : Kaldor et al.. 1990 . Within (AGS) and re-reviewed to incorporate further subdivision of nodular sclerosing HD. and staging was according to the Ann Arbor classification (Carbone et al.. 1971 )' modified to include the use of computed axial tomography as an alternative to lymphography for the detection of intra-abdominal disease from 1980.
Clinical details of the patient population are shown in Tables I and II. Serum. stored at -20'C from 1978 onwards from initial presentation was available in 60 cases. These cases were not selected in any other way. A double antibody radioimmunoassay (Pharmacia) was used to quantify A microglobulin levels in these specimens.
Treatment at presentation
Chemotherapy Between 1968 and early 1984. the treatment of choice was cyclical combination chemotherapy With mus- (1992) . 65, [429] [430] [431] [432] [433] [434] [435] [436] [437] Dose The ratio of cumulative therapy administered to planned therapy over the first six cycles was retrospectively calculated in the patients for whom remission was achieved (Appendix). Delays in administration of chemotherapy were also evaluated in this group. The dose:time analysis showed that 85% of the patients received more than 85% of the therapy on time (Figure 2 ).
Radiotherapy Twenty-four of 164 patients received irradiation electively in addition to the chemotherapy, eight prior to chemotherapy, becuase of pressing clinical problems (in these patients, the response to MVPP has not been distinguished from that of radiotherapy) and 16 after completion of chemotherapy, to sites of previous bulk disease or persistent residual abnormality. The response to radiotherapy has been documented separately for the latter.
Definition of response This has been documented at the completion of six cycles of chemotherapy, unless death or obvious progression had intervened. The criteria upon which the description of the response are based changed over the 22 years of study, the precision with which 'complete remission' can be defined having increased. Consequently, the distinction between complete remission (CR) and partial remission (PR) has changed. To accommodate this, PR was subdivided as described below. It is important to note that GPR is not necessarily equivalent to the newly designated CR(u) (Lister et al., 1989 (Armitage. 1971) . Duration of remission and overall survival were plotted using standard life table methods (Kaplan & Meier. 1958 ) and compared using the log rank method (Peto et al.. 1977) . The significance of prognostic factors in determining the achievement of CR was evaluated by logistic regression analysis. whereas duration of CR and overall survival differences were determined using a stepwise linear regression method based on Cox's proportional hazards model (Cox. 1972) .
Results

Initial Presentation
Response to therapy Complete remission (CR) The total number of patients in whom CR was achieved with first line (97) and second line (five) therapy was 102 164 (62%).
Fifteen patients died before completion of planned treatment. before response to treatment could be adequately assessed; three were known to have advancing disease at the time of death. There were nine deaths due to infective complications. one of cardiac failure. one from pulmonary embolus and one from cardiac tamponade due to haemopericardium.
The effects of presentation age. gender. serum albumin. erythrocyte sedimentation rate (ESR), alkaline phosphatase, lymphocyte counts. B symptoms. drug dose intensity, histology and serum 2 microglobulin on achievement of remission were determined by univanrate and multivariate analyses (the A microglobulin results were from a smaller set of patients).
Prognostic factors significant for the achievement of CR by logistic regression analysis were albumin (P = 0.0002) and stage (IIIB vs IV. P = 0.004) ( Table IV) . The CR rate increased with increasing albumin. from 36% (13 36) for albumin <33 g 1. to 61% (46 76) for albumin 33-39 g 1. to 81% (34 42) for albumin 40 g 1. The CR rate for patients stage IIIB disease was 75% compared with 50% in patients with stage IV disease. Stage and albumin were independent. unrelated factors. significant on multivariate analysis. On the reduced set of 60 patients with known P2 microglobulin levels, age and lymphocyte count were again significant. Serum R microglobulin was significant on univariate (P = 0.003, Figure 7 ), but not on multivariate analysis. On the basis of these prognostic factors, patients can be divided into two distinct groups-a good prognostic group. in which none of the patients have any of the adverse factors (age less than 45 years, lymphocyte count more than 0.75 x 1091 and histology apart from lymphocyte depletion). and a poor prognostic group, where patients have one or more of the adverse factors. The difference between the two groups is statistically very significant (P<0.001) (Figure 8 ).
Survivalfollowing recurrence The median survival from first recurrence is 4 years, being better when second remission was achieved than the rest. The median survival of patients who achieve second CR is 12 years. Advanced age correlated adversely with survival, (age greater than 40. P = 0.04; age greater than 45, P <0.009; age greater than 50, P = 0.009). Extranodal disease at time of recurrence was a significant adverse prognostic factor on univariate but not on multivariate analysis. Gender, albumin level at recurrence or duration of first remission were not significant in correlating for better survival. MOPP or similar regimens (Longo et al.. 1986 : Selby et al.. 1990 : Ranson et al.. 1991) . although some of the difference may be accounted for by variations in the patient populations, particularlv with respect to age and general debility (as reflected by hypoalbuminaemia). additional therapy or differences in the criteria for documenting complete remission. Regardless of this. however. it is clear that either persisting with the same treatment beyond six cycles, or changing it at that time to an alternative is not a fruitful approach since this only increased the complete remission rate to 620o. and more important. the survival of this 6% was markedly inferior to that of the initial 5900. Failure to demonstrate significant efficacy of the ABVD programme (Santro & Bonadonna. 1979) for patients with refractory disease at St Bartholomew's Hospital. in contrast to the experience in Milan (Santoro et al.. 1979 (Santoro et al.. : 1982 . may well relate solelv to the fact that it was 'left too late'. The equivalent efficacy of the ABVD and MOPP in inducing remission provided the rationale for testing non-cross-resistant and hybrid combinations (Santoro et al.. 1982 : Klimo & Connors. 1985 Somers et al.. 1990 ). Second malignancies accounted for 10% of the deaths in remitters. being the single most important cause of mortality after HD. The risk of second malignancy seems to be increased in patients who receive additional therapy-6 7 remitters who develop second malignancy had had extra chemotherapy as maintenance or additional irradiation. Three other patients who developed second malignancy following recurrence had been retreated with combination chemotherapy. The increased risk of secondary malignancy with increasing therapy is well recognised. particularly following irradiation (Coleman. 1986 : Somers et al., 1990 . Data on more than 12.411 patients treated for HD in different centres were pooled and analysed in 1989 (Somers et al.. 1990 ). The cumulative incidence of second malignancy over a 20-year follow-up period approaches 18.6%0 with solid tumours' accounting for the majority of late malignancies. In this group of patients treated with MVPP with a minimum follow-up of 6 years there has only been one instance of frank acute myeloid leukaemia which occurred at the same time as progressive Hodgkin's disease at second recurrence. and one myelodysplastic syndrome in third remission. In the NCI series (Longo et al.. 1986) . there were 13 cases of acute leukaemia. from a total cohort of 198 patients, 12 of which occurred in patients who had received both MOPP and irradiation. In contrast to these results. Kaldor et al. (19%) . in a case controlled study of 163 should be allowed to detract from the significant benefit it has brought to the majority of those who received it. The challenge is to look forward and do better.
Causes of death
